- Home
- CHRS vs HGLB Comparison
CHRS vs HGLB Comparison
Compare CHRS & HGLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- HGLB
- Stock Information
- Founded
- CHRS 2010
- HGLB 1998
- Country
- CHRS United States
- HGLB United States
- Employees
- CHRS N/A
- HGLB N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- HGLB Trusts Except Educational Religious and Charitable
- Sector
- CHRS Health Care
- HGLB Finance
- Exchange
- CHRS Nasdaq
- HGLB Nasdaq
- Market Cap
- CHRS 84.2M
- HGLB 195.7M
- IPO Year
- CHRS 2014
- HGLB N/A
- Fundamental
- Price
- CHRS $0.82
- HGLB $8.63
- Analyst Decision
- CHRS Buy
- HGLB
- Analyst Count
- CHRS 3
- HGLB 0
- Target Price
- CHRS $4.68
- HGLB N/A
- AVG Volume (30 Days)
- CHRS 1.3M
- HGLB 91.8K
- Earning Date
- CHRS 08-07-2025
- HGLB 01-01-0001
- Dividend Yield
- CHRS N/A
- HGLB 13.16%
- EPS Growth
- CHRS N/A
- HGLB N/A
- EPS
- CHRS N/A
- HGLB N/A
- Revenue
- CHRS $272,251,000.00
- HGLB N/A
- Revenue This Year
- CHRS N/A
- HGLB N/A
- Revenue Next Year
- CHRS $106.56
- HGLB N/A
- P/E Ratio
- CHRS $1.90
- HGLB N/A
- Revenue Growth
- CHRS 19.87
- HGLB N/A
- 52 Week Low
- CHRS $0.66
- HGLB $6.42
- 52 Week High
- CHRS $2.43
- HGLB $9.45
- Technical
- Relative Strength Index (RSI)
- CHRS 53.65
- HGLB 47.82
- Support Level
- CHRS $0.72
- HGLB $8.46
- Resistance Level
- CHRS $0.77
- HGLB $8.98
- Average True Range (ATR)
- CHRS 0.04
- HGLB 0.19
- MACD
- CHRS 0.01
- HGLB -0.05
- Stochastic Oscillator
- CHRS 91.74
- HGLB 25.99
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About HGLB Highland Global Allocation Fund
Highland Global Allocation Fund is a diversified, closed-end management investment company. The investment objective of the Fund is to seek long-term growth of capital and future income. The Fund seeks to achieve its investment objectives by investing in a portfolio of U.S. and foreign equity, debt, and money market securities. It may also invest in senior loans to domestic or foreign corporations, partnerships, and other entities that operate in a variety of industries and geographic regions.